Glioblastoma Multiforme Treatment with Clinical Trials for Surgical Resection (Aminolevulinic Acid)

Neurosurgery Clinics of North America

Volumn 23, Issue 3, 2012, Pages 371-377

  Roberts, David W ^a,b,c   Valdés, Pablo A ^a,b,d   Harris, Brent T ^e   Hartov, Alexander ^c,d   Fan, Xiaoyao ^c,d   Ji, Songbai ^c,d   Leblond, Frederic ^c,d   Tosteson, Tor D ^a,c   Wilson, Brian C ^f   Paulsen, Keith D ^b,c,d  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c NORRIS COTTON CANCER CENTER   (United States)

^d DARTMOUTH COLLEGE   (United States)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

5 ALA; Fluorescence; Glioma; Surgery

Indexed keywords

AMINOLEVULINIC ACID;

CANCER GRADING; CANCER INFILTRATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); CORRELATION ANALYSIS; FLUORESCENCE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; INTRAOPERATIVE PERIOD; PERFORMANCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SURGICAL MICROSCOPE;

AMINOLEVULINIC ACID; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FLUORESCENT DYES; GLIOBLASTOMA; HUMANS; MICROSCOPY, FLUORESCENCE; NEOPLASM, RESIDUAL; NEUROSURGICAL PROCEDURES; PHOTOSENSITIZING AGENTS; TREATMENT OUTCOME;

EID: 84862979491     PISSN: 10423680     EISSN: 15581349     Source Type: Journal    
DOI: 10.1016/j.nec.2012.04.001     Document Type: Review

References (8)

1. Stummer W., Novotny A., Stepp H., et al. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 2000, 93(6):1003-1013.
2. Stummer W., Pichlmeier U., Meinel T., et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006, 7(5):392-401.
3. Curran W.J., Scott C.B., Horton J., et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993, 85(9):704-710.
4. Pichlmeier U., Bink A., Schackert G., et al. Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro Oncol 2008, 10(6):1025-1034.
5. Stummer W., Tonn J.C., Mehdorn H.M., et al. Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. J Neurosurg 2011, 114(3):613-623.
6. Roberts D.W., Valdes P.A., Harris B.T., et al. Coregistered fluorescence-enhanced tumor resection of malignant glioma: relationships between delta-aminolevulinic acid-induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. J Neurosurg 2011, 114(3):595-603.
7. Valdes P.A., Kim A., Brantsch M., et al. Delta-aminolevulinic acid-induced protoporphyrin IX concentration correlates with histopathologic markers of malignancy in human gliomas: the need for quantitative fluorescence-guided resection to identify regions of increasing malignancy. Neuro Oncol 2011, 13(8):846-856.
8. Valdes P.A., Leblond F., Kim A., et al. Quantitative fluorescence in intracranial tumor: implications for ALA-induced PpIX as an intraoperative biomarker. J Neurosurg 2011, 115(1):11-17.